期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
ARIG inhibition improves the prognosis of liver cancer through autophagy regulation and tumor immunity enhancement
1
作者 Jiaqi Chen Xiaoting Zhang +2 位作者 weijian hu Yang Bai Yi Zhou 《Genes & Diseases》 SCIE CSCD 2023年第5期1731-1734,共4页
Currently, the primary treatment for hepatocellular carcinoma (HCC) is a comprehensive treatment based on surgery.1 In the case of advanced HCC that may not be removed surgically, additional issues, such as drug resis... Currently, the primary treatment for hepatocellular carcinoma (HCC) is a comprehensive treatment based on surgery.1 In the case of advanced HCC that may not be removed surgically, additional issues, such as drug resistance and drug inefficacy with long-term use of chemotherapeutic drugs, highlight the pressing need for new treatment strategies.2 Autophagy plays an essential role in cellular physiology, which was reported to modulate components of the immune system.3 Autophagy-related immune genes (ARIGs) are linked to both autophagy and immunity. Here we identified histone deacetylase 1 (HDAC1), an ARIG strongly expressed in HCC, as a therapeutic target.4 Then valproic acid (VPA), a specific inhibitor of HDAC1,5 was used to treat liver cancer in vitro and in vivo. The results demonstrated that VPA could significantly induce autophagy and apoptosis of Hepa1-6 cells and inhibit tumor growth in vivo. This effect could be related to the regulation of autophagy and tumor immune microenvironment by VPA. 展开更多
关键词 DRUGS liver treatment
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部